Evaluating dual direct-acting antivirals against persistent COVID-19
Researchers assessed the efficiency of dual direct-acting antivirals in treating persistent coronavirus disease 2019 (COVID-19).
Stay updated with breaking news from Research Square. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Researchers assessed the efficiency of dual direct-acting antivirals in treating persistent coronavirus disease 2019 (COVID-19).
The triglyceride-glucose index correlated with subclinical heart failure with preserved ejection fraction in asymptomatic patients with type 2 diabetes.
Among patients with intermediate coronary lesions not undergoing revascularization, prediabetes, as defined by the International Expert Committee, best predicted increased risk for cardiovascular events.
Researchers investigated the associations between clinical characteristics of coronavirus disease 2019 (COVID-19) and immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Among women with postsurgical hypoparathyroidism, areal bone mineral density was higher, and there was no increase in fracture rate nor risk in a small cross-sectional study.